Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.78IPCO.TO 0.08DC.A.TO 0.1NESN-SIX 0MCK 9.94GOOG -1.89XLV -0.22TEVA 0.83
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.95
-0.02 (0.07%)
as of Aug 25, 2026, 1:34:22 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 24, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as its revenue streams have been impacted by the end of the COVID vaccine boom and a looming patent cliff. Many experts express concerns over the company's limited pipeline for new blockbuster drugs, especially as previous successful drugs have come off patent. Despite these challenges, Pfizer offers an attractive dividend yield which has been highlighted across many reviews, providing a tempting incentive for investors. Some experts suggest it might be a good long-term hold due to potential growth in areas like oncology and obesity, although the company's future growth prospects remain uncertain. The general sentiment suggests that while some see PFE as a value play, caution is advised given the current dynamics of its business model.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY

Pfizer Inc(PFE)

May 04, 2001
At a good price now. Good pipeline.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$43.46

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 03, 2001
At fair market value. Now ($45). No room to grow.
Photo of Ross HealyRoss HealyUnlock Rating
$42.25

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 25, 2001
(Was a top pick on Jan 8 down 3%) Still likes. Just bought more. Has the least amount of patent expiries.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.91

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2001
Long term. Strong growth/company.
Photo of Neil MurdockNeil MurdockUnlock Rating
$40.70

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 10, 2001
High quality and fast growth. A little too high now.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$41.00

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 04, 2001
Good pipeline. Good defensive play.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$39.75

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 27, 2001
Going through some problems.
Photo of David DriscollDavid DriscollUnlock Rating
$39.98

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 23, 2001
Great Products. Good mngmnt. At a good price. Best company in the pharmaceutical space. Great cash flow
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$37.53

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 22, 2001
Great business model. Good pipelines. At a good price now.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$35.67

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 12, 2001
Excellent long term hold. Good drugs in the pipeline
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.35

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 07, 2001
Not cheap, but good growth. Good holdings on patents.
Photo of David McLeanDavid McLeanUnlock Rating
$41.95

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 06, 2001
Has done well until recently. Drug stocks in US are extended now. Will tech sell off move into drug sector?
Photo of Ross HealyRoss HealyUnlock Rating
$43.10

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 30, 2001
Good company. When rates go down, valuations go up
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$44.28

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 30, 2001
Buying in low $40's
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$44.28

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 08, 2001
Expects a very good year. Buy on DIPS
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$41.88

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 871 to 885 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -2.98$99.89
TFPM 0$
OGC.TO -0.83$42.39
SLB 0.045$54.045
ARG.TO 0.33$8.55

Today's Top Picks

SII.TO 3.78$190.97
IPCO.TO 0.08$35.3
DC.A.TO 0.1$5.25
NESN-SIX 0$
MCK 9.94$883.73

Popular Articles

Latest Sell Signals

RKLB -1.05$67.23
INTC 1.21$88.47
MSFT 1.63$488.94
WSP.TO -0.96$191.32
CLS.TO 10.72$418.08

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like